Your browser doesn't support javascript.
loading
RETRACTED: Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial.
Abd-Elsalam, Sherief; Salama, Marwa; Soliman, Shaimaa; Naguib, Ahmed Mohamed; Ibrahim, Ibrahim S; Torky, Mohamed; El Ghafar, Mohamed Samir Abd; Abdul-Baki, Enas Abdul-Raouf M; Elhendawy, Mohammed.
Afiliación
  • Abd-Elsalam S; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Salama M; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Soliman S; Public Health and Community Medicine, Menoufia University, Menoufia, Egypt.
  • Naguib AM; Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Ibrahim IS; Chest Department, Tanta University, Tanta, Egypt.
  • Torky M; Chest Department, Tanta University, Tanta, Egypt.
  • El Ghafar MSA; Department of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Abdul-Baki EAM; School of Biotechnology, Badr University in Cairo, Badr City, Cairo 11829, Egypt.
  • Elhendawy M; Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt.
Am J Trop Med Hyg ; 106(3): 886-890, 2021 09 10.
Article en En | MEDLINE | ID: mdl-34649223
RETRACTED ARTICLE: To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30-60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P < 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P = 0.469). The mortality rate was comparable between the two groups (P = 0.602). Mortality was significantly associated with older age, elevated C-reactive protein levels, elevated D-dimer, and the need for mechanical ventilation (P = 0.039, 0.003, 0.001, and < 0.001 respectively). Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19. Its use, in addition to standard care including dexamethasone, should be considered, particularly in low- and middle-income countries when other effective options are scarce.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2021 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2021 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Estados Unidos